ELI LILLY AND COMPANY OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
ELI LILLY AND COMPANY (LLY) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of -$55.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2018-02-20
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-12-31 was -$29.60M, a 160.78% decline year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-09-30 was $4.20M, a 83.91% decline year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-06-30 was -$11.50M, a 212.75% decline year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-03-31 was -$18.10M, a 530.95% decline year-over-year.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2017 was -$55.00M, a 161.66% decline from fiscal 2016.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2016 was $89.20M.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2015 was -$48.50M.
- ELI LILLY AND COMPANY oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2014 was -$56.70M, a 179.19% decline from fiscal 2013.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$29.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$25.40M derived: sum of 2 quarters · filed 2018-02-20 | -$36.90M derived: sum of 3 quarters · filed 2018-02-20 | -$55.00M 10-K · filed 2018-02-20 | ||||
| 2017-09-30 | $4.20M 10-Q · filed 2017-10-27 | -$7.30M derived: sum of 2 quarters · filed 2017-10-27 | -$25.40M 10-Q · filed 2017-10-27 | $23.30M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2017-06-30 | -$11.50M 10-Q · filed 2017-07-28 | -$29.60M 10-Q · filed 2017-07-28 | $19.10M derived: sum of 3 quarters · filed 2018-02-20 | $45.20M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2017-03-31 | -$18.10M 10-Q · filed 2017-05-01 | $30.60M derived: sum of 2 quarters · filed 2018-02-20 | $56.70M derived: sum of 3 quarters · filed 2018-02-20 | $66.90M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-12-31 | $48.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $74.80M derived: sum of 2 quarters · filed 2018-02-20 | $85.00M derived: sum of 3 quarters · filed 2018-02-20 | $89.20M 10-K · filed 2018-02-20 | ||||
| 2016-09-30 | $26.10M 10-Q · filed 2017-10-27 | $36.30M derived: sum of 2 quarters · filed 2017-10-27 | $40.50M 10-Q · filed 2017-10-27 | -$56.20M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-06-30 | $10.20M 10-Q · filed 2017-07-28 | $14.40M 10-Q · filed 2017-07-28 | -$82.30M derived: sum of 3 quarters · filed 2018-02-20 | -$22.70M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2016-03-31 | $4.20M 10-Q · filed 2017-05-01 | -$92.50M derived: sum of 2 quarters · filed 2018-02-20 | -$32.90M derived: sum of 3 quarters · filed 2018-02-20 | -$51.50M derived: sum of 4 quarters · filed 2018-02-20 | ||||
| 2015-12-31 | -$96.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$37.10M derived: sum of 2 quarters · filed 2018-02-20 | -$55.70M derived: sum of 3 quarters · filed 2018-02-20 | -$48.50M 10-K · filed 2018-02-20 | ||||
| 2015-09-30 | $59.60M 10-Q · filed 2016-10-28 | $41.00M derived: sum of 2 quarters · filed 2016-10-28 | $48.20M 10-Q · filed 2016-10-28 | -$52.00M derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-06-30 | -$18.60M 10-Q · filed 2016-07-28 | $18.60M 10-Q · filed 2015-07-30 | $11.40M 10-Q · filed 2016-07-28 | -$11.40M 10-Q · filed 2015-07-30 | -$111.60M derived: sum of 3 quarters · filed 2017-02-21 | -$88.80M derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2015-03-31 | $30.00M 10-Q · filed 2016-04-29 | -$30.00M 10-Q · filed 2015-04-30 | -$93.00M derived: sum of 2 quarters · filed 2017-02-21 | -$70.20M derived: sum of 3 quarters · filed 2017-02-21 | -$47.90M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2014-12-31 | -$123.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | -$100.20M derived: sum of 2 quarters · filed 2017-02-21 | -$77.90M derived: sum of 3 quarters · filed 2017-02-21 | -$56.70M 10-K · filed 2017-02-21 | ||||
| 2014-09-30 | $22.80M 10-Q · filed 2015-10-30 | $45.10M derived: sum of 2 quarters · filed 2015-10-30 | $66.30M 10-Q · filed 2015-10-30 | $169.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $22.30M 10-Q · filed 2015-07-30 | $43.50M 10-Q · filed 2015-07-30 | $146.20M derived: sum of 3 quarters · filed 2016-02-19 | $113.30M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $21.20M 10-Q · filed 2015-04-30 | -$21.20M 10-Q · filed 2014-04-28 | $123.90M derived: sum of 2 quarters · filed 2016-02-19 | $91.00M derived: sum of 3 quarters · filed 2016-02-19 | $102.60M derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $102.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $69.80M derived: sum of 2 quarters · filed 2016-02-19 | $81.40M derived: sum of 3 quarters · filed 2016-02-19 | $71.60M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | -$32.90M 10-Q · filed 2014-10-29 | $32.90M 10-Q · filed 2013-10-30 | -$21.30M derived: sum of 2 quarters · filed 2014-10-29 | -$31.10M 10-Q · filed 2014-10-29 | $31.10M 10-Q · filed 2013-10-30 | |||
| 2013-06-30 | $11.60M 10-Q · filed 2014-07-28 | $1.80M 10-Q · filed 2014-07-28 | ||||||
| 2013-03-31 | $10.10M 10-Q · filed 2014-04-28 | |||||||
| 2012-12-31 | $30.80M 10-K · filed 2015-02-19 | |||||||
| 2011-12-31 | -$64.40M 10-K · filed 2014-02-19 | $64.40M 10-K · filed 2012-02-24 | ||||||
| 2010-12-31 | $27.30M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |